Ocata Therapeutics

Recent stem cell pubs & news: reprogramming, chromatin, single-cell, Astellas, & more

stem-cell-news-pigs-organ-transplants

What new papers and news in the stem cell sphere caught your eye? Here are some recent items that seem notable to me. Diabetes relief in mice by glucose-sensing insulin-secreting human α-cells. This paper reports cellular reprogramming to insulin-producing cells in mice. They reprogrammed α-cells with Pdx1 and MafA proteins. ‘Mitophagy inhibits amyloid-β and tau pathology and reverses …

Recent stem cell pubs & news: reprogramming, chromatin, single-cell, Astellas, & more Read More »

Brief quote from Bob Lanza on Ocata acquisition by Astellas

Robert-Lanza

I asked Ocata CSO, Bob Lanza, for a comment on the big news of the acquisition of the company by Astellas. Here’s what he had to say: “I can say that this is an exciting time for regenerative medicine.  The merger should greatly accelerate the pace of discovery, and, I hope, lead to treatments for …

Brief quote from Bob Lanza on Ocata acquisition by Astellas Read More »

Ocata bought by Astellas of Japan: initial perspectives on end of an era

Astellas

Bombshell news in the stem cell field as Ocata Therapeutics (OCAT; formerly Advanced Cell Technology or ACT) is reportedly to be acquired by Astellas Pharma, Inc. The offer for purchase of OCAT will be $8.50/share or almost $380 million. For more details see this detailed PDF from Astellas. This quote on the deal form Ocata: “Paul …

Ocata bought by Astellas of Japan: initial perspectives on end of an era Read More »

New UK trial & Ocata: stem cell hope on vision impairment

Peter-Coffey-Lyndon-Da-Cruz

We’ve been hearing a lot this week about an important new clinical study for vision loss (macular degeneration) in the UK. This team is using retinal pigmented epithelial cells (RPEs) made from embryonic stem cells (ESC). They are now testing safety. The new work in the UK is Moorfields Eye Hospital is a great addition …

New UK trial & Ocata: stem cell hope on vision impairment Read More »

Sally Temple on adult RPEs for vision impairment, IND, & more

Sally-Temple-cells

At the recent RPI stem cell and bioengineering meeting, the Neural Stem Cell Institute’s Sally Temple talked about her group’s intriguing retinal pigmented epithelial cell (RPE) research. With the broad focus of attention in the world of RPEs mostly on those derived from either human ESC or IPSC, it was exciting to here about the …

Sally Temple on adult RPEs for vision impairment, IND, & more Read More »

ACT reinventing itself with new name Ocata Therapeutics

advanced-cell-technology

Here is a link to the Ocata website, marking the start of a new era for what was formerly Advanced Cell Technology or ACT. It’s been a big summer for stem cell biotech Advanced Cell Technology (ACT; stock ACTCD) as it continues what I would call a process of reinventing itself. What’s been happening? ACT recently …

ACT reinventing itself with new name Ocata Therapeutics Read More »